Intra-Cellular Therapies Total Assets 2013-2022 | ITCI
Intra-Cellular Therapies total assets from 2013 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
- Intra-Cellular Therapies total assets for the quarter ending March 31, 2022 were $0.869B, a 28.78% increase year-over-year.
- Intra-Cellular Therapies total assets for 2021 were $0.49B, a 31.7% decline from 2020.
- Intra-Cellular Therapies total assets for 2020 were $0.717B, a 185.57% increase from 2019.
- Intra-Cellular Therapies total assets for 2019 were $0.251B, a 29.68% decline from 2018.
Intra-Cellular Therapies Annual Total Assets
(Millions of US $) |
| 2021 |
$490 |
| 2020 |
$717 |
| 2019 |
$251 |
| 2018 |
$357 |
| 2017 |
$471 |
| 2016 |
$389 |
| 2015 |
$484 |
| 2014 |
$131 |
| 2013 |
$38 |
| 2012 |
$20 |
Intra-Cellular Therapies Quarterly Total Assets
(Millions of US $) |
| 2022-03-31 |
$869 |
| 2021-12-31 |
$490 |
| 2021-09-30 |
$557 |
| 2021-06-30 |
$626 |
| 2021-03-31 |
$674 |
| 2020-12-31 |
$717 |
| 2020-09-30 |
$771 |
| 2020-06-30 |
$441 |
| 2020-03-31 |
$481 |
| 2019-12-31 |
$251 |
| 2019-09-30 |
$281 |
| 2019-06-30 |
$310 |
| 2019-03-31 |
$343 |
| 2018-12-31 |
$357 |
| 2018-09-30 |
$386 |
| 2018-06-30 |
$412 |
| 2018-03-31 |
$446 |
| 2017-12-31 |
$471 |
| 2017-09-30 |
$334 |
| 2017-06-30 |
$350 |
| 2017-03-31 |
$372 |
| 2016-12-31 |
$389 |
| 2016-09-30 |
$543 |
| 2016-06-30 |
$448 |
| 2016-03-31 |
$464 |
| 2015-12-31 |
$484 |
| 2015-09-30 |
$513 |
| 2015-06-30 |
$213 |
| 2015-03-31 |
$237 |
| 2014-12-31 |
$131 |
| 2014-09-30 |
$138 |
| 2014-06-30 |
$141 |
| 2014-03-31 |
$147 |
| 2013-12-31 |
$38 |
| 2013-09-30 |
$47 |
| 2013-06-30 |
$0 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
$0 |
| 2012-09-30 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$5.459B |
$0.084B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
